Filter by
Selections
November 12, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment at AASLD Liver Meeting
Read MoreNovember 1, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming November 2021 Conferences
Read MoreOctober 25, 2021
Arrowhead Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreOctober 12, 2021
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-C3 for Treatment of Complement Mediated Diseases
Read MoreSeptember 30, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
Read MoreSeptember 29, 2021